Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Mannkind's Business Segments
Mannkind's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
All Other Segments
Total Revenue
$ 90
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- All Other Segments100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| All Other Segments | $ 90 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product Revenue62%
- Product37.6%
- Royalty36.3%
- License and Service26.1%
- Furoscix17.2%
- Afrezza16.9%
- V Go3.5%
- Manufacturing Services2.7%
- Service1.7%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product Revenue | $ 56 | 62% |
| Product | $ 34 | 37.6% |
| Royalty | $ 33 | 36.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Mannkind
Mannkind Corporation is a biopharmaceutical company that operates in the United States. The company is dedicated to the development and commercialization of therapeutic products for patients with various medical conditions. Specifically, Mannkind Corporation focuses on developing therapeutic products for the treatment of pulmonary arterial hypertension, diabetes and cancer.
One of the main products developed by Mannkind Corporation is Afrezza, a rapid-acting insulin inhalation powder that is used to treat diabetes. Afrezza is an inhalable insulin that works faster than traditional insulin injections and does not require a needle. This product is patented and provides a unique approach to the treatment of diabetes.
Apart from Afrezza, Mannkind Corporation has a number of other products in development. For pulmonary arterial hypertension, the company is developing TRE-Xi, an inhaled treatment that targets the smooth muscle cells in the pulmonary arteries. Additionally, Mannkind Corporation is also developing new technology for the delivery of inhaled drugs, which is known as the Technosphere platform technology. This proprietary platform allows for the delivery of drugs using inhalation and offers enhanced product performance and increased stability.
The company has also established various collaborations with other pharmaceutical companies to develop and commercialize its products. For instance, Mannkind Corporation has a co-promotion agreement with Sanofi-Aventis for the promotion of Afrezza globally. Similarly, the company has also entered into partnerships with United Therapeutics to develop therapies for the treatment of pulmonary arterial hypertension.
Mannkind Corporation was founded in 1991 and is headquartered in California. The company has a workforce of approximately 200 employees and has a market capitalization of approximately $255 million USD. Mannkind Corporation is listed on the NASDAQ stock exchange under the ticker symbol MNKD.
One of the main products developed by Mannkind Corporation is Afrezza, a rapid-acting insulin inhalation powder that is used to treat diabetes. Afrezza is an inhalable insulin that works faster than traditional insulin injections and does not require a needle. This product is patented and provides a unique approach to the treatment of diabetes.
Apart from Afrezza, Mannkind Corporation has a number of other products in development. For pulmonary arterial hypertension, the company is developing TRE-Xi, an inhaled treatment that targets the smooth muscle cells in the pulmonary arteries. Additionally, Mannkind Corporation is also developing new technology for the delivery of inhaled drugs, which is known as the Technosphere platform technology. This proprietary platform allows for the delivery of drugs using inhalation and offers enhanced product performance and increased stability.
The company has also established various collaborations with other pharmaceutical companies to develop and commercialize its products. For instance, Mannkind Corporation has a co-promotion agreement with Sanofi-Aventis for the promotion of Afrezza globally. Similarly, the company has also entered into partnerships with United Therapeutics to develop therapies for the treatment of pulmonary arterial hypertension.
Mannkind Corporation was founded in 1991 and is headquartered in California. The company has a workforce of approximately 200 employees and has a market capitalization of approximately $255 million USD. Mannkind Corporation is listed on the NASDAQ stock exchange under the ticker symbol MNKD.
MannKind Corporation is a prominent biopharmaceutical company specializing in the development and commercialization of innovative inhaled therapeutic products tailored for patients with conditions such as diabetes and pulmonary arterial hypertension. The companys endeavors are encapsulated in distinct segments, a growing portfolio of products, and comprehensive support services designed to enhance patient care and treatment outcomes.
Segments
1. Afrezza:
- The Afrezza segment is primarily dedicated to the development and commercialization of Afrezza, which is an inhaled insulin therapy. This product is particularly significant for patients with diabetes, as it provides a rapid-acting insulin delivery method that can help manage blood glucose levels more effectively than traditional subcutaneous insulin injections. The unique formulation of Afrezza allows for quicker onset and offset of action, which can closely mimic the body’s natural insulin response to food intake.
2. Technosphere:
- This segment leverages MannKind’s proprietary Technosphere platform, a transformative drug-delivery technology that enables the administration of medications in a powder form through inhalation. The Technosphere platform is designed to optimize the performance of various therapeutic compounds, allowing for enhanced bioavailability and faster therapeutic action compared to traditional administration routes.
Products
1. Afrezza (Inhaled Insulin):
- Afrezza is the flagship product of MannKind Corporation and has gained FDA approval as the only inhaled insulin currently available on the market. It is delivered via a pocket-sized inhaler and is indicated for the treatment of adults with diabetes, both Type 1 and Type The product is notable for its convenience and rapid absorption properties, which make it an attractive option for patients seeking alternatives to injectable insulin therapies.
2. Treprostinil Technosphere:
- Under development within the Technosphere segment, Treprostinil Technosphere is an inhaled formulation aimed at treating pulmonary arterial hypertension (PAH). It utilizes the Technosphere platform to deliver treprostinil—a potent vasodilator—directly to the lungs, which can facilitate an effective response while minimizing systemic side effects.
3. Rize:
- Rize is another product in the development pipeline, targeting acute migraine attacks. This innovative inhalation therapy aims to provide rapid relief of migraine symptoms by utilizing the Technosphere technology. The focus of Rize is to deliver migraine medication effectively through inhalation, allowing for a faster onset of relief compared to traditional oral medications.
4. Other Products:
- MannKind is actively researching and developing additional therapies using the Technosphere platform to address various medical conditions, expanding its portfolio in the inhaled therapeutic area.
Services
1. Patient Support Services:
- MannKind offers a robust suite of patient support services designed to assist individuals prescribed Afrezza. These services include:
- Insurance Assistance: Helping patients navigate insurance coverage options to minimize out-of-pocket costs associated with their treatment.
- Educational Resources: Providing educational materials about the proper use of Afrezza, including training on the inhaler and information on managing diabetes effectively.
- Ongoing Support: Offering continuous support through follow-up communications and access to healthcare professionals who can help address any treatment-related questions or concerns.
2. Scientific Research:
- The company is committed to advancing medical science through significant investment in scientific research and development. This includes:
- Conducting preclinical and clinical trials to assess the safety and efficacy of new products formulated using the Technosphere platform.
- Collaborating with research institutions and clinical experts to explore further applications of inhaled therapies in various disease states, thereby enhancing the potential impact of its product pipeline.
Conclusion
In summary, MannKind Corporation is dedicated to innovating inhaled therapeutic products that cater to the needs of patients with diabetes and pulmonary arterial hypertension. Through its specialized segments, such as Afrezza and Technosphere, the company continually works to deliver effective treatment options while backing its products with comprehensive patient support services and ongoing scientific research. The integration of advanced inhalation technology positions MannKind at the forefront of inhaled therapeutics, as it aims to improve the quality of care for patients across multiple health conditions.
Segments
1. Afrezza:
- The Afrezza segment is primarily dedicated to the development and commercialization of Afrezza, which is an inhaled insulin therapy. This product is particularly significant for patients with diabetes, as it provides a rapid-acting insulin delivery method that can help manage blood glucose levels more effectively than traditional subcutaneous insulin injections. The unique formulation of Afrezza allows for quicker onset and offset of action, which can closely mimic the body’s natural insulin response to food intake.
2. Technosphere:
- This segment leverages MannKind’s proprietary Technosphere platform, a transformative drug-delivery technology that enables the administration of medications in a powder form through inhalation. The Technosphere platform is designed to optimize the performance of various therapeutic compounds, allowing for enhanced bioavailability and faster therapeutic action compared to traditional administration routes.
Products
1. Afrezza (Inhaled Insulin):
- Afrezza is the flagship product of MannKind Corporation and has gained FDA approval as the only inhaled insulin currently available on the market. It is delivered via a pocket-sized inhaler and is indicated for the treatment of adults with diabetes, both Type 1 and Type The product is notable for its convenience and rapid absorption properties, which make it an attractive option for patients seeking alternatives to injectable insulin therapies.
2. Treprostinil Technosphere:
- Under development within the Technosphere segment, Treprostinil Technosphere is an inhaled formulation aimed at treating pulmonary arterial hypertension (PAH). It utilizes the Technosphere platform to deliver treprostinil—a potent vasodilator—directly to the lungs, which can facilitate an effective response while minimizing systemic side effects.
3. Rize:
- Rize is another product in the development pipeline, targeting acute migraine attacks. This innovative inhalation therapy aims to provide rapid relief of migraine symptoms by utilizing the Technosphere technology. The focus of Rize is to deliver migraine medication effectively through inhalation, allowing for a faster onset of relief compared to traditional oral medications.
4. Other Products:
- MannKind is actively researching and developing additional therapies using the Technosphere platform to address various medical conditions, expanding its portfolio in the inhaled therapeutic area.
Services
1. Patient Support Services:
- MannKind offers a robust suite of patient support services designed to assist individuals prescribed Afrezza. These services include:
- Insurance Assistance: Helping patients navigate insurance coverage options to minimize out-of-pocket costs associated with their treatment.
- Educational Resources: Providing educational materials about the proper use of Afrezza, including training on the inhaler and information on managing diabetes effectively.
- Ongoing Support: Offering continuous support through follow-up communications and access to healthcare professionals who can help address any treatment-related questions or concerns.
2. Scientific Research:
- The company is committed to advancing medical science through significant investment in scientific research and development. This includes:
- Conducting preclinical and clinical trials to assess the safety and efficacy of new products formulated using the Technosphere platform.
- Collaborating with research institutions and clinical experts to explore further applications of inhaled therapies in various disease states, thereby enhancing the potential impact of its product pipeline.
Conclusion
In summary, MannKind Corporation is dedicated to innovating inhaled therapeutic products that cater to the needs of patients with diabetes and pulmonary arterial hypertension. Through its specialized segments, such as Afrezza and Technosphere, the company continually works to deliver effective treatment options while backing its products with comprehensive patient support services and ongoing scientific research. The integration of advanced inhalation technology positions MannKind at the forefront of inhaled therapeutics, as it aims to improve the quality of care for patients across multiple health conditions.